Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Go back to Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting| FATE THERAPEUTICS (NASDAQ: FATE) | Delayed: 2.54 +0.02 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.52 | 52 Week High | $4.76 | |||
| Open | $2.59 | 52 Week Low | $1.46 | |||
| Day High | $2.61 | P/E | N/A | |||
| Day Low | $2.52 | EPS | $-1.91 | |||
| Volume | 422,222 | |||||
